12/11
08:21 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
12/11
08:21 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
12/10
06:20 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.
12/10
12:15 pm
tcrx
City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference [Yahoo! Finance]
Medium
Report
City of Hope doctors and scientists present research on novel cancer therapies at American Society of Hematology (ASH) annual conference [Yahoo! Finance]
12/9
05:50 pm
tcrx
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
High
Report
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition [Yahoo! Finance]
12/9
05:45 pm
tcrx
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
High
Report
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
12/5
08:10 am
tcrx
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years [Yahoo! Finance]
Medium
Report
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years [Yahoo! Finance]
12/5
08:00 am
tcrx
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
Medium
Report
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
12/2
07:05 am
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy [Yahoo! Finance]
Low
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy [Yahoo! Finance]
12/2
07:00 am
tcrx
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
Low
Report
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
11/15
08:04 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
11/14
05:32 am
tcrx
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
12:36 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/12
09:49 am
tcrx
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
Medium
Report
TScan Therapeutics GAAP EPS of -$0.25, revenue of $1.04M Nov. 12, 2024 9:48 AM ET By: Urvi Shah , SA News Editor [Seeking Alpha]
11/12
07:00 am
tcrx
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/7
06:39 am
tcrx
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
11/6
08:07 am
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Medium
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
11/5
06:24 pm
tcrx
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
Low
Report
TScan Therapeutics, Inc. (NASDAQ: TCRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.
11/5
09:15 am
tcrx
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
Medium
Report
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
10/4
09:05 am
tcrx
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
Medium
Report
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting